Competitive Generic Therapies: Off-Patent Drugs With 3 Sources
✉ Email this page to a colleague
This table lists drugs which, despite having no patents or regulatory protections, have a limited number of active sources.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Strength |
---|---|---|---|---|---|---|---|---|---|---|
Glenmark Generics | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 202229-001 | Jul 16, 2013 | AB | RX | No | Yes | 333MG |
Mylan | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 200142-001 | Mar 11, 2014 | AB | RX | No | No | 333MG |
Zydus Pharms | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 205995-001 | May 26, 2017 | AB | RX | No | No | 333MG |
Eugia Pharma | ACYCLOVIR SODIUM | acyclovir sodium | INJECTABLE;INJECTION | 203701-001 | Oct 11, 2013 | AP | RX | No | No | EQ 50MG BASE/ML |
Fresenius Kabi Usa | ACYCLOVIR SODIUM | acyclovir sodium | INJECTABLE;INJECTION | 074930-001 | May 13, 1998 | AP | RX | No | Yes | EQ 50MG BASE/ML |
Zydus Pharms | ACYCLOVIR SODIUM | acyclovir sodium | INJECTABLE;INJECTION | 206535-001 | Aug 31, 2018 | AP | RX | No | No | EQ 50MG BASE/ML |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Strength |